Article Figures & Data
Tables
- Table 1.
Characteristics of the patients with SLE-associated refractory immune thrombocytopenia who were treated with thrombopoietin-receptor agonists.
Case (ref) Age, yrs Sex Previous Treatments Thrombopoietin-receptor Agonist Dose Response Time to Response Adverse Events #1 (PC) 69 F CS, IVIG, splenectomy, RTX Eltrombopag 25 mg/day Yes 2 weeks No #2 (PC) 39 F CS, IVIG, CYC, azathioprine, RTX Romiplostim 2 mcg/kg/week, further increased to 7 μg/kg/week Yes 2 weeks No #3 (6) 44 M CS, IVIG, azathioprine, RTX, CYC Romiplostim 2 mcg/kg/week Yes 3 weeks No #4 (7) 34 F CS, IVIG, RTX, CYC Romiplostim (previously eltrombopag without response) 3 mcg/kg/week Yes 6 days No #5 (8) 19 F CS, IVIG, RTX Romiplostim NS Yes NS Kidney-limited thrombotic microangiopathy #6 (9) 55 F CS, RTX, CSA Eltrombopag 50 mg/day Yes 2 weeks No #7 (10) NS NS NS NS NS No NS NS -
PC: present case; CS: corticosteroids; IVIG: intravenous immunoglobulin; RTX: rituximab; CYC: cyclophosphamide; CSA: cyclosporine; NS: not specified.
-